inclusion criteria: 1. patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); 2. has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; 3. the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; 4. male or female subjects aged 18 to 80 years (including 18 and 80 years); 5. subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; 6. subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.

inclusion criteria: 1. patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); 2. has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; 3. the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; 4. male or female subjects aged 18 to 80 years (including 18 and 80 years); 5. subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; 6. subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.

inclusion criteria: patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; male or female subjects aged 18 to 80 years (including 18 and 80 years); subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.

inclusion criteria: patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; male or female subjects aged 18 to 80 years (including 18 and 80 years); subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.

inclusion criteria: 1. patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); 2. has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; 3. the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; 4. male or female subjects aged 18 to 80 years (including 18 and 80 years); 5. subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; 6. subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.

inclusion criteria: 1. patients diagnosed with mild or moderate covid-19 (as per the diagnosis and treatment protocol for novel coronavirus pneumonia (trial, 8th edition), china, or clinical management of covid-19, who); 2. has at least one covid-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization; 3. the sars-cov-2 nasopharyngeal nucleic acid is tested to be positive (rt-pcr), igm (-)/igg (-) or igm (+)/igg (-) within 3 days before randomization; 4. male or female subjects aged 18 to 80 years (including 18 and 80 years); 5. subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period; 6. subjects voluntarily sign the informed consent form (icf) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.